- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Prothena Corporation plc (PRTA)
Prothena Corporation plc stock price live, this page displays NASDAQ PRTA stock exchange data. View the PRTA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Prothena Corporation plc real time stock price chart below.
What Is the Prothena Corporation plc Stock Price Today?
The Prothena Corporation plc stock price today is 6.88.
What Is the Stock Symbol for Prothena Corporation plc?
The stock symbol for Prothena Corporation plc is ""PRTA.""
What Stock Exchange Does Prothena Corporation plc Trade On?
Prothena Corporation plc is listed and trades on the NASDAQ stock exchange.
Is Prothena Corporation plc a Good Stock to Buy?
Determining whether Prothena Corporation plc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PRTA quote. (ISIN: IE00B91XRN20)
What Is the Prothena Corporation plc Stock Price Today?
The Prothena Corporation plc stock price today is 6.88.
What Is the Stock Symbol for Prothena Corporation plc?
The stock symbol for Prothena Corporation plc is ""PRTA.""
What Stock Exchange Does Prothena Corporation plc Trade On?
Prothena Corporation plc is listed and trades on the NASDAQ stock exchange.
Is Prothena Corporation plc a Good Stock to Buy?
Determining whether Prothena Corporation plc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PRTA quote. (ISIN: IE00B91XRN20)
NASDAQ
Currency in USD
6.88
-0.05(-0.72%)
Closed·
After Hours
6.99+0.11(+1.60%)
·
Fair Value
An estimate of a Prothena's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.74
7.33
52 wk Range
4.32
24.10
PRTA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 4 days
More Info
Fair Value
An estimate of a Prothena's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.747.33
52 wk Range
4.3224.10
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PRTA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Prothena's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
24.29
Upside
+252.99%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral
Prothena Corporation plc Company Profile
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson’s disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer’s disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer’s disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer’s disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Compare PRTA to Peers and Sector
Metrics to compare | PRTA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPRTAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.4x | −2.2x | −0.5x | |
PEG Ratio | −0.09 | 0.00 | 0.00 | |
Price/Book | 0.8x | 5.5x | 2.6x | |
Price / LTM Sales | 2.7x | 9.7x | 3.3x | |
Upside (Analyst Target) | 156.4% | 301.6% | 42.4% | |
Fair Value Upside | Unlock | 29.4% | 7.2% | Unlock |
Analyst Ratings
4 Buy
3 Hold
1 Sell
Ratings:
8 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 24.29
(+252.99% Upside)
Earnings
Latest Release
May 08, 2025
EPS / Forecast
-1.12 / -1.23
Revenue / Forecast
2.83M / 9.54M
People Also Watch
FAQ
What Stock Exchange Does Prothena Trade On?
Prothena is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Prothena?
The stock symbol for Prothena is "PRTA."
What Is the Prothena Market Cap?
As of today, Prothena market cap is 370.33M.
What Is Prothena's Earnings Per Share (TTM)?
The Prothena EPS (TTM) is -2.05.
When Is the Next Prothena Earnings Date?
Prothena will release its next earnings report on 03 Aug 2025.
From a Technical Analysis Perspective, Is PRTA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Prothena Stock Split?
Prothena has split 0 times.
How Many Employees Does Prothena Have?
Prothena has 163 employees.
What is the current trading status of Prothena (PRTA)?
As of 30 Jul 2025, Prothena (PRTA) is trading at a price of 6.88, with a previous close of 6.93. The stock has fluctuated within a day range of 6.74 to 7.33, while its 52-week range spans from 4.32 to 24.10.
What Is Prothena (PRTA) Price Target According to Analysts?
The average 12-month price target for Prothena is USD24.28571, with a high estimate of USD81 and a low estimate of USD4. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +252.99% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.